FO
VRTX icon

FT Options’s Vertex Pharmaceuticals VRTX Stock Holding History

FT Options’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$209K Buy
46,200
+6,500
+16% +$978K 0.32% 63
2017
Q2 		$96K Sell
39,700
-10,200
-20% -$1.23M 0.17% 83
2017
Q1 		$366K Buy
49,900
+19,000
+61% +$1.67M 0.48% 55
2016
Q4 		$894K Buy
30,900
+18,600
+151% +$1.51M 1.03% 26
2016
Q3 		$429K Buy
+12,300
New +$1.16M 0.34% 61

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FT Options's VRTX Position: Q2 2017 in Review

FT Options sold out of Vertex Pharmaceuticals (VRTX) in Q2 2017, closing a stake of 4,582 shares — an estimated $552K sold.

FT Options first reported a position in VRTX in Q3 2016 and held it in 3 quarters. The position peaked at $703K in Q4 2016. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

  • FT Options reported no remaining Vertex Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • FT Options sold 4,582 Vertex Pharmaceuticals shares in Q2 2017, an estimated $552K.
  • FT Options first reported a position in Vertex Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • FT Options's Vertex Pharmaceuticals position peaked at $703K in Q4 2016.
  • 582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.